Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E.

Abstract

CDC announces the availability of a new heptavalent botulinum antitoxin (HBAT, Cangene Corporation) through a CDC-sponsored Food and Drug Administration (FDA) Investigational New Drug (IND) protocol. HBAT replaces a licensed bivalent botulinum antitoxin AB and an investigational monovalent botulinum antitoxin E (BAT-AB and BAT-E, Sanofi Pasteur) with expiration of these products on March 12, 2010. As of March 13, 2010, HBAT became the only botulinum antitoxin available in the United States for naturally occurring noninfant botulism.

• Authors: Centers for Disease Control and Prevention (CDC)
• Journal: MMWR. Morbidity and mortality weekly report (MMWR Morb Mortal Wkly Rep) Vol. 59 Issue 10 Pg. 299 (Mar 19 2010) ISSN: 1545-861X [Electronic] United States
• PMID: 20300057 (Publication Type: Journal Article)

Chemical References

• Botulinum Antitoxin
• Drugs, Investigational

Topics

• Botulinum Antitoxin (administration & dosage, immunology)
• Botulism (drug therapy)
• Centers for Disease Control and Prevention, U.S.
• Drugs, Investigational
• Humans
• United States